Xenon Pharmaceuticals (XENE) Peer Comparison

$60.13

$0.13 (0.22%)

As on 02-Sep-2026 10:37EDT

Market cap

$5,809 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.8

Div. Yield

0 %

Edit

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Market cap ($ Mln)	5,809	2,167	3,678	345	430
Revenue ($ Mln)	--	312	66	0	59
Net Profit ($ Mln)	-409.20	314.11	-164.66	-37.54	-3.25
Net Margin (%)	--	100.84	-248.83	134,079.79	-5.49
RoE (%)	-44.86	52.52	-17.68	-79.49	-8.35
Price to Earnings	--	7.14	--	--	--
Price-To-Book	4.83	3.57	4.48	9.49	9.71

Cashflow
Ratios

Cashflow ($ Mln)

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Cash From Operating Activities	-279.12	135.66	-131.30	-29.06	-12.47
Cash Flow from Investing Activities	218.00	-32.77	87.75	-2.19	--
Cash from Financing Activities	117.11	-106.11	14.08	43.88	22.63
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
ROCE (%)	-51.11	51.61	-13.12	-67.28	-40.15
ROE (%)	-44.86	52.52	-17.68	-79.49	-8.35
ROA (%)	-27.75	42.65	-11.64	-60.11	-3.23
EBIT Margin (%)	--	54.20	-304.58	133,972.64	-4.19
Net Margin (%)	-4,612.13	100.84	-248.83	134,079.79	-5.49
Cash Profit Margin (%)	--	0.00	0.00	3.35	0.00

Growth Ratios

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Revenue Growth (%)	--	19.76	101.28	-100.20	77.83
EBIT Growth (%)	3.41	151.91	23.59	-26.93	70.81
Net Profit Growth (%)	-47.07	418.03	0.61	-26.91	72.99
EPS Growth (%)	-34.29	434.98	2.53	-6.40	73.38
Book Value Growth (%)	55.33	96.66	-13.08	12.47	531.86

Valuation Ratios

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Price / Earnings	-10.27	7.70	-6.98	-11.41	-24.64
Price / Book Value	6.11	3.81	1.06	6.66	6.85
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-8.80	14.79	-4.24	-9.61	-27.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.03	0.01	0.00	0.00
Current Ratio	21.02	5.42	12.77	6.72	5.85
Quick Ratio	21.02	4.97	12.63	6.72	5.66
Interest Coverage	--	17.75	-11.19	--	-2.43

Operating Efficiency Ratios

	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Debtors to sales (%)	18.28	13.21	144.21	0.00	39.29
Asset Turnover	0.00	0.42	0.05	0.00	0.59
Receivable days	69.15	50.32	596.85	--	147.53
Inventory Days	--	474.76	40.15	--	127.22
Payable days	643.10	47.52	377.52	--	381.73
Cash Conversion Cycle	--	477.57	259.48	--	-106.97

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly